Core Viewpoint - TaiLi Bio is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies, with its core candidate drug TSN1611 being a selective oral KRAS G12D inhibitor [1][3]. Group 1: Company Overview - TaiLi Bio was established in 2017 and has submitted its listing application to the Hong Kong Stock Exchange [1]. - The company has a pipeline that includes four candidate drugs, with TSN1611 currently in Phase 2 clinical trials in the US and China [3]. Group 2: Financial Performance - The company reported net losses of 70.461 million yuan and 123 million yuan for the first three quarters of 2024 and 2025, respectively [1][6]. - Research and development expenses for the same periods were 72.813 million yuan and 91.17 million yuan [6]. Group 3: Business Model and Strategy - TaiLi Bio's business model focuses on the independent discovery and development of innovative drugs in the oncology field, particularly small molecule drugs and ADC candidates [3]. - The company aims to accelerate the clinical development and commercialization of TSN1611 and plans to pursue external collaborations to maximize the global value of its technology platform and product pipeline [3][4]. Group 4: Research and Development - The company has established three core self-developed technology platforms that provide a competitive advantage in the development of small molecules and ADCs [3]. - As of January 23, 2026, TaiLi Bio holds 97 patents and patent applications [6]. Group 5: Regulatory Status - As of the latest update, TaiLi Bio has not received any regulatory approvals for its candidate drugs and has not generated any revenue from product sales [6].

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a highly selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets KRAS G12D, one of the most common oncogenic driver mutations, which has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials for non-small cell lung cancer (NSCLC) in China [1] - Additional candidates in the pipeline include TSN222, a Phase 2 clinical candidate, and two preclinical candidates, TSNA1789 and TSNA3399 [1]

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets the KRAS G12D mutation, which is one of the most common oncogenic driver mutations and has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials in China for the treatment of non-small cell lung cancer (NSCLC) [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Tyligand Bioscience Ltd. 泰勵生物有限公司 * (the "Company") (Incorporated in the Cayman Islands with limited liability) WARNING The publication ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Tyligand Bioscience Ltd. 泰勵生物有限公司* （「本公司」） （於開曼群島註冊成立的有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長註冊的本公 司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件中 的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並 ...